GH
Guardant Health Inc
NASDAQ: GH · HEALTHCARE · DIAGNOSTICS & RESEARCH
$96.71
-5.60% today
Updated 2026-06-05
Market cap
$17.45B
P/E ratio
—
P/S ratio
16.16x
EPS (TTM)
$-3.40
Dividend yield
—
52W range
$40 – $134
Volume
2.3M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A7.0
Quality
B+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$140.91
+45.70%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy16 Buy1 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 48.30% QoQ
+ Debt/equity -9.26x — low leverage
Risks
- Altman Z -1.58 — distress zone
- Thin margins at -40.10%
- Negative free cash flow $-71.20M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $449.54M | $563.95M | $739.02M | $982.02M | $1.08B |
| Net income | $-654.59M | $-479.45M | $-436.37M | $-416.28M | $-112.08M |
| EPS | — | — | — | — | $-3.40 |
| Free cash flow | $-386.92M | $-345.46M | $-274.94M | $-233.07M | $-71.20M |
| Profit margin | -145.61% | -85.02% | -59.05% | -42.39% | -40.10% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-05 | ELTOUKHY, HELMY | Sale | 49,716 | $125.57 |
| 2026-06-05 | ELTOUKHY, HELMY | Sale | 33,843 | $126.33 |
| 2026-06-05 | ELTOUKHY, HELMY | Sale | 13,787 | $128.25 |
Peer comparison
Smart narrative
Guardant Health Inc trades at $96.71. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -1.58, it sits in the distress. TTM revenue stands at $1.08B. with profit margins at -40.10%.
Frequently asked questions
What is Guardant Health Inc's stock price?
Guardant Health Inc (GH) trades at $96.71, on a P/S of 16.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Guardant Health Inc overvalued?
Guardant Health Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Guardant Health Inc (GH)?
The 12-month analyst consensus target is $140.91, about 45.7% above the current $96.71. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Guardant Health Inc's revenue?
Guardant Health Inc's trailing twelve-month revenue is $1.08B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Guardant Health Inc's Altman Z-Score is -1.58, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio16.16x
ROE-4,584.00%
Beta1.62
50D MA$102.83
200D MA$92.63
Shares out0.13B
Float0.13B
Short ratio—
Avg volume2.3M
Performance
1 week+0.00%
1 month+32.33%
3 months+44.08%
YTD+22.98%
1 year—
3 years—
5 years—